ReWalk Robotics (LFWD) 10-Q 15 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 11, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Central Index Key	1,607,962
Amendment Flag	false
Trading Symbol	RWLK
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,633,885

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 8,818	$ 14,567
Trade receivable, net	1,566	1,103
Prepaid expenses and other current assets	2,018	1,625
Inventories	3,480	3,643
Total current assets	15,882	20,938
LONG-TERM ASSETS
Other long term assets	1,082	1,085
Property and equipment, net	756	840
Total long-term assets	1,838	1,925
Total assets	17,720	22,863
CURRENT LIABILITIES
Current maturities of long term loan	6,441	6,441
Trade payables	2,873	1,811
Employees and payroll accruals	926	872
Deferred revenues and customers advances	129	123
Other current liabilities	428	480
Total current liabilities	10,797	9,727
LONG-TERM LIABILITIES
Long term loan, net of current maturities	7,796	8,911
Deferred revenues	330	262
Other long-term liabilities	296	256
Total long-term liabilities	8,422	9,429
Total liabilities	19,219	19,156
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders' equity (deficiency):
Share capital, Ordinary shares NIS 0.01 par value- Authorized: 250,000,000 shares at March 31, 2018 and December 31, 2017; Issued and outstanding: 30,510,455 and 30,003,639 shares at March 31, 2018 and December 31, 2017, respectively	86	84
Receivables on account of shares	(42)
Additional paid-in capital	136,027	134,843
Accumulated deficit	(137,570)	(131,220)
Total shareholders' equity (deficiency)	(1,499)	3,707
Total liabilities and shareholders' equity (deficiency)	$ 17,720	$ 22,863

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - ₪ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Ordinary shares, par value (in ILS per share)	₪ 0.01	₪ 0.01
Ordinary shares, authorized	250,000,000	250,000,000
Ordinary shares, issued	30,510,455	30,003,639
Ordinary shares, outstanding	30,510,455	30,003,639

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenues	$ 1,579	$ 2,499
Cost of revenues	897	1,450
Gross profit	682	1,049
Operating expenses:
Research and development, net	2,151	1,430
Sales and marketing	2,336	3,133
General and administrative	2,037	2,141
Total operating expenses	6,524	6,704
Operating loss	(5,842)	(5,655)
Financial expenses, net	485	731
Loss before income taxes	(6,327)	(6,386)
Income taxes		14
Net loss	$ (6,327)	$ (6,400)
Net loss per ordinary share, basic and diluted	$ (0.21)	$ (0.39)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted	30,049,293	16,455,257

Condensed Statements of Changes

Condensed Statements of Changes In Shareholders' Equity (Deficiency) (Unaudited) - USD ($) $ in Thousands		Ordinary Share		Receivables on account of shares	Additional paid-in capital	Accumulated deficit	Total
Balance at Dec. 31, 2016		$ 45			$ 114,707	$ (106,492)	$ 8,260
Balance, shares at Dec. 31, 2016		16,338,257
Cumulative effect to stock based compensation and retained earning from adoption of a new accounting standard					11	(11)
Share-based compensation to employees and non-employees					3,654		3,654
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees		$ 1			37		38
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		166,748
Issuance of ordinary shares in at-the-market offering, net of issuance expenses		$ 16			9,293		9,309
Issuance of ordinary shares in at-the-market offering, net of issuance expenses, shares		5,613,084
Issuance of ordinary shares in follow-on public offering, net of issuance expenses in an amount of $1,117		$ 22			7,141		7,163
Issuance of ordinary shares in follow-on public offering, net of issuance expenses in an amount of $1,117, shares		7,885,550
Net loss						(24,717)	(24,717)
Balance at Dec. 31, 2017		$ 84			134,843	(131,220)	3,707
Balance, shares at Dec. 31, 2017		30,003,639
Cumulative effect to stock based compensation and retained earning from adoption of a new accounting standard						(23)	(23)
Share-based compensation to employees and non-employees					796		796
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees			[1]
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		117,416
Issuance of ordinary shares in at-the-market offering, net of issuance expenses	[2]	$ 2		$ (42)	388		348
Issuance of ordinary shares in at-the-market offering, net of issuance expenses, shares	[2]	389,400
Net loss						(6,327)	(6,327)
Balance at Mar. 31, 2018		$ 86		$ (42)	$ 136,027	$ (137,570)	$ (1,499)
Balance, shares at Mar. 31, 2018		30,510,455
[1]	Represents an amount lower than $1.
[2]	See Note 7e to the condensed consolidated financial statements.

Condensed Statements of Change6

Condensed Statements of Changes In Shareholders' Equity (Deficiency) (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Atm Offering Program
Issuance costs	$ 50	$ 467
Public Stock Offering
Issuance costs		$ 1,117

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Cash flows used in operating activities:
Net loss		$ (6,327)	$ (6,400)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		113	180
Share-based compensation to employees and non- employees		796	851
Deferred taxes		(14)	(47)
Financial expenses related to long term loan			33
Changes in assets and liabilities:
Trade receivables, net		(433)	(147)
Prepaid expenses and other assets		180	(204)
Inventories		134	188
Trade payables		409	(438)
Employees and payroll accruals		54	(313)
Deferred revenues and advances from customers		74	127
Other liabilities		(12)	141
Net cash used in operating activities		(5,026)	(6,029)
Cash flows used in investing activities:
Purchase of property and equipment			(10)
Net cash used in investing activities			(10)
Cash flows used in financing activities:
Issuance of ordinary shares upon exercise of stock options by employees and non employees			20
Repayment of long term loan		(1,115)	(1,168)
Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of $12	[1]	386	658
Net cash used in financing activities		(729)	(490)
Decrease in cash, cash equivalents, and restricted cash		(5,755)	(6,529)
Cash, cash equivalents, and restricted cash at beginning of period		15,423	24,498
Cash, cash equivalents, and restricted cash at end of period		9,668	17,969
Supplemental disclosures of non-cash flow information
Proceeds on account of ordinary shares in at-the-market offering not yet received		(42)
At-the-market offering expenses not yet paid		38	47
Private placement issuance cost not yet paid	[2]	615
Classification of inventory to property and equipment, net		29	29
Supplemental cash flow information:
Cash and cash equivalents		8,818	17,128
Restricted cash included in other long term assets		850	841
Total Cash, cash equivalents, and restricted cash		$ 9,668	$ 17,969
[1]	See Note 7e to the condensed consolidated financial statements.
[2]	See Note 10b to the condensed consolidated financial statements

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Statement of Cash Flows [Abstract]
Issuance expenses paid	$ 12

General

General	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1:- GENERAL a. ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. b. RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) incorporated under the laws of Germany on January 14, 2013. c. The Company is designing, developing and commercializing the ReWalk system, an innovative exoskeleton that allow wheelchair-bound persons with mobility impairments or other medical conditions to stand and walk once again. The ReWalk system consists of a light wearable brace support suit which integrates motors at the joints, rechargeable batteries, an array of sensors and a computer-based control system to power knee and hip movement. There are currently two types of products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by individuals at home and in their communities and is custom-fitted for each user. ReWalk Rehabilitation is designed for the clinical rehabilitation environment where it provides individuals access to valuable exercise and therapy. It also enables individuals to evaluate their capacity for using ReWalk Personal system in the future. d. The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in Germany and the United States, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with rehabilitation centers and the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI markets and sells products mainly in the United States and Canada. RRG sell the Company’s products mainly in Germany and Europe. e. During the three months ended March 31, 2018, the Company issued and sold 389,400 ordinary shares at an average price of $1.13 per share under its $25 million ATM Offering Program (as defined in Note 7e below). The gross proceeds to the Company were $440 thousand, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $50 thousand were $390 thousand. As a result, from the inception of the ATM Offering Program in May 2016 until March 31, 2018, the Company has issued and sold 6,694,546 ordinary shares at an average price of $2.21 per share under its ATM Offering Program, with gross proceeds of $14.8 million, and net aggregate proceeds of $13.8 million after deducting commissions, fees and offering expenses in the amount of $948 thousand. The Company could raise up to a remaining $10.2 million under its ATM Offering Program, subject to a limitation on sales under the Company’s effective Form S-3 limiting sales under such Form S-3 to $13.7 million during any 12-month period. See Note 7e below for more information about the Company’s ATM Offering Program. f. The Company has an accumulated deficit in the total amount of $137.6 million as of March 31, 2018 and further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, issuances under the Company's ATM Offering Program, or other future public or private issuances of equity and debt securities, including the private placement of ordinary shares to Timwell Corporation Limited, a Hong Kong entity, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company require more funds than anticipated during the next 12 months or in later periods. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The consolidated financial statements for the three months ended March 31, 2018 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Financial Statements	3 Months Ended
	Mar. 31, 2018
Unaudited Interim Condensed Consolidated Financial Statements
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	NOTE 2:- UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company's (i) consolidated financial position as of March 31, 2018, (ii) consolidated results of operations for the three months ended March 31, 2018 and (iii) consolidated cash flows for the three months ended March 31, 2018. The results for the three months periods ended March 31, 2018, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3:- SIGNIFICANT ACCOUNTING POLICIES a. The significant accounting policies applied in the audited consolidated financial statements of the Company as disclosed in the Company's annual report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 8, 2018, are applied consistently in these unaudited interim condensed consolidated financial statements, except the below: b. Revenue Recognition The Company generate revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. On January 1, 2018, we adopted Topic 606 using the modified retrospective method for contracts that were not completed as of January 1, 2018. Under the modified retrospective method, we recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. This adjustment did not have a material impact on our condensed consolidated financial statements. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under Revenue Recognition ("Topic 605"). The adoption of Topic 606 represents a change in accounting principle that will provide financial statement readers with enhanced revenue recognition disclosures. In accordance with Topic 606, revenue is recognized when obligations under the terms of a contract with our customer are satisfied; generally this occurs with the transfer of control of our products or services. Revenue is measured as the amount of consideration to which we expect to be entitled in exchange for transferring products or providing services. To achieve this core principle, the Company applies the following five steps: 1. Identify the contract with a customer A contract with a customer exists when (i) the Company enters into a written agreement with a customer that defines each party's rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) both parties to the contract are committed to perform their respective obligations, (iii) the contract has commercial substance, and (iv) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer's intent and ability to pay the promised consideration. The Company applies judgment in determining the customer's ability and intention to pay, which is based on a variety of factors including the customer's payment history or, in the case of a new customer, published credit and financial information pertaining to the customer. 2. Identify the performance obligations in the contract Performance obligations promised in a contract are identified based on the products or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the product or service either on its own or together with other resources that are readily available from the Company, and are distinct in the context of the contract, whereby the transfer of the products or services is separately identifiable from other promises in the contract. 3. Determine the transaction price The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer. To the extent the transaction price is variable, revenue is recognized at an amount equal the consideration to which the Company expects to be entitled. This estimate includes customer sales incentives which are accounted for as a reduction to revenue and estimated using either the expected value method or the most likely amount method, depending on the nature of the program. As a result of the Company's adoption of this standard, the majority of the amounts that were historically classified as bad debt expense, primarily related to self-payers customers, are now considered an implicit price concession in determining net revenue. Accordingly, the Company recognized uncollectible balances associated with self-payers customers as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within general and administrative expenses. Shipping and handling costs charged to customers are included in net sales. Determining the transaction price requires significant judgment, which is discussed by revenue category in further detail below. In practice, we do not offer extended payment terms beyond one year to customers. As such, we do not adjust our consideration for financing arrangements. 4. Allocate the transaction price to performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis unless a portion of the variable consideration related to the contract is allocated entirely to a performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. 5. Recognize revenue when or as the Company satisfies a performance obligation The Company generally satisfies performance obligations at a point in time, once the customer has obtained the legal title to the items purchased or service provided. For systems sold to rehabilitation facilities, the Company includes training and considers the elements in the arrangement to be a single performance obligation. In accordance with ASC 606, the Company has concluded that the training is essential to the functionality of the Company’s systems. Therefore the Company recognizes revenue for the system and training only after delivery in accordance with the agreement delivery terms to the customer and after the training has been completed. For sales of Personal systems to end users, and for sales of Personal or Rehabilitation systems to third party distributors, the Company does not provide training to the end user as this training is completed by the Rehabilitation centers or by the distributor that have previously completed the ReWalk Training program. Therefore the Company recognizes revenue in such sales upon delivery. Revenue is recognized based on the transaction price at the time the related performance obligation is satisfied by transferring a promised product or service to a customer. The Company generally does not grant a right of return for its products. There have been a few occasions in which the Company experienced a return of its products. Therefore, the Company records reductions to revenue for expected future product returns based on the Company’s historical experience. Disaggregation of Revenues March 31, March 31, 2018 2017 Units placed $ 1,528 $ 2,443 Spare parts and warranties 51 56 Total Revenues $ 1,579 $ 2,499 Units placed We currently offer two products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is currently designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is currently designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides individuals access to valuable exercise and therapy. It also enables individuals to evaluate their capacity for using ReWalk Personal in the future. Units placed includes revenue from sales of a ReWalk Personal or ReWalk Rehabilitation. We also offer a Rent-to-Purchase model in which we recognize revenue according to the agreed rental monthly fee. For units placed, we transfer control and recognize a sale or a rental revenue when title has passed to our customer. Each unit placed is considered an independent, unbundled performance obligation. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. For spare part sales, we transfer control and recognize a sale when title has passed to our customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, we updated our service policy to include a five- year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. Contract balances March 31, December 31, 2018 2017 Trade receivable, net $ 1,566 $ 1,103 Deferred revenues (1) $ 459 $ 385 (1) $72 thousand of December 31, 2017 deferred revenues balance were recognized as revenues during the three months ended March 31, 2018. The Company has applied the practical expedient allowed within the guidance to expense sales commissions when incurred as the amortization period would be for one year or less. Typical timing of payment The timing of satisfaction of our performance obligations does not significantly vary from the typical timing of payment. Typical payment terms are based on payment terms as established in our contracts. For some contracts we may be entitled to receive an advance payment. Transaction price allocated to remaining performance obligations For the three months ended March 31, 2018, revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material. The Company’s unfilled performance obligations as of March 31, 2018 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $459 thousand, which is fulfilled over 1-5 years. c. Recent Accounting Pronouncements: Share Based Compensation Cash Flows On November 17, 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force) Recent Accounting Pronouncements Not Yet Adopted Leases whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a manner similar to the accounting under existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840, "Leases". The guidance is effective for the interim and annual periods beginning on or after December 15, 2018. The Company is currently evaluating the impact that ASU 2016-02 will have on its consolidated financial statements and related disclosures. Income Taxes Income Tax Accounting Implications of the Tax Cuts and Jobs Act d. Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. March 31, December 31, 2018 2017 Customer A 33 % *) Customer B *) 17 % Customer C *) 14 % Customer D *) 10 % *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of March 31, 2018 and December 31, 2017 trade receivables are presented net of allowance for doubtful accounts in the amount of $125 thousand and net of sales return reserve of $105 thousand as of March 31, 2018 and December 31, 2017. e. Warranty provision The Company provided a two-year standard warranty for its products, In the beginning of 2018 we updated our service policy for new devices sold to include five-year warranties. The Company determined that the first two years of warranty is an assurance-type warranty and records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in thousands Balance at December 31, 2017 $ 488 Provision 58 Usage (70 ) Balance at March 31, 2018 $ 476

Inventory

Inventory	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
INVENTORY	NOTE 4:- INVENTORY The components of inventory are as follows (in thousands): March 31, December 31, 2018 2017 Finished products $ 3,480 $ 3,643 $ 3,480 $ 3,643

Commitments and Contingent Liab

Commitments and Contingent Liabilities	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 5:- COMMITMENTS AND CONTINGENT LIABILITIES a. Purchase commitments: The Company has contractual obligations to purchase goods from its contract manufacturer. Purchase obligations do not include contracts that may be canceled without penalty. As of March 31, 2018, non-cancelable outstanding obligations amounted to approximately $317 thousand. b. Lease commitment: the Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2018 and 2025 (the “lease agreements”). The future minimum lease commitments of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises, that are in effect as of March 31, 2018, are as follows (in thousands): 2018 $ 441 2019 586 2020 594 2021 593 2022 601 And Thereafter 1,106 Total $ 3,921 RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2018 and 2020. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $57 thousand as of March 31, 2018. c. Royalties: The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (the “IIA”) and Israel-U.S. Binational Industrial Research and Development Foundation (the “BIRD”). Since the Company’s inception through March 31, 2018, the Company received funding from the IIA and BIRD in the total amount of $1.97 million and $500 thousand, respectively. Out of the $1.97 million in funding from the IIA, a total amount of $1.57 million were royalty bearing grants (as of March 31, 2018, the Company paid royalties to the IIA in the total amount of $50 thousand), while a total amount of $400 thousand was received in consideration of 5,237 convertible preferred A shares, which converted after our initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1. The Company is obligated to pay royalties to the IIA, amounting to 3%-3.5% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. The Company was obligated to pay royalties to BIRD amounting to 5% of the sales of the products and other related revenues generated from such projects, up to 150% of the grants received. For the three months ended March 31, 2018 there were no royalties expenses recorded in cost of revenues. As of March 31, 2018, the contingent liability to the IIA amounted to $1.5 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases: (a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the research and development activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) if such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient. d. Liens: As discussed in Note 6 to the Company’s audited consolidated financial statements in its annual report on Form 10-K for the fiscal year ended December 31, 2017 (the “2017 Form 10-K”), the Company is party to a loan agreement, as amended (the “Loan Agreement”), with Kreos Capital V (Expert Fund) Limited (“Kreos”), pursuant to which Kreos extended a $20 million line of credit to the Company. In connection with the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests. The Company's other long-term assets in the amount of $850 thousand have been pledged to third parties as a security in respect to lease agreements . e. Legal Claims: Occasionally the Company is involved in various claims, lawsuits, regulatory examinations, investigations and other legal matters arising, for the most part, in the ordinary course of business. The outcome of litigation and other legal matters is inherently uncertain. In making a determination regarding accruals, using available information, the Company evaluates the likelihood of an unfavorable outcome in legal or regulatory proceedings to which the Company is a party and records a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. Where the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for any potential litigation loss. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of our defenses, and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from the Company’s current estimates. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to the Company’s consolidated results of operations, liquidity or financial condition. As set forth below, between September 2016 and January 2017, eight substantially similar putative securities class actions were filed against the Company. As of March 31, 2018, four of these actions have been dismissed on procedural grounds, one was voluntarily dismissed and three are pending, including two actions which have been consolidated and one action brought by the plaintiffs whose actions were dismissed. Dismissed Actions: • ’ IPO •On January 24, 2017, a substantially similar class action was commenced in the United States District Court for the Northern District of California (Case No. 4:17-cv-362) against the same defendants as in the California State Court Actions plus certain additional defendants. This action is referred to as the “California Federal Court Action.” On March 23, 2017, this case was voluntarily dismissed. Pending Actions: •On or about October 31, 2016, a class action with claims substantially similar to the California State Court Actions was commenced in the Massachusetts Superior Court, Suffolk County, by a different plaintiff (Civ. Action No. 16-3336), alleging claims under Section 11 of the Securities Act against the Company, certain of the Company’s current and former directors and officers, and the underwriters of the Company’s IPO, and alleging claims under Section 15 of the Securities Act against the Company and certain of the Company’s current and former directors and officers. •On or about November 30, 2016, a substantially similar class action was commenced in the Massachusetts Superior Court, Suffolk County, by a different plaintiff (Civ. Action No. 16-3670) alleging claims under Sections 11 and 15 of the Securities Act against the same defendants as in the action commenced on October 31, 2016, and also alleging claims under Section 12(a)(2) of the Securities Act against the Company, certain of the Company’s current and former directors and officers, and the underwriters of the Company’s IPO. This action was ordered consolidated in the Massachusetts Superior Court, Suffolk County on January 9, 2017 with the action commenced on October 31, 2016, and the two actions are referred to as the “Consolidated Massachusetts State Court Actions.” The plaintiffs in the Consolidated Massachusetts State Court Actions filed a consolidated amended complaint on March 20, 2017. The Company moved to dismiss the Consolidated Massachusetts State Court Actions on June 2, 2017. On December 6, 2017, at a hearing to address the motion to dismiss of the non-U.S. defendants, the court, in light of the pending argument of the motion to dismiss in the Massachusetts Federal Court Action (as defined below), reconsidered its previous decision denying a stay and, subsequently entered an order staying the action. •On or about January 31, 2017, a substantially similar class action was commenced in the United States District Court for the District of Massachusetts (Case No. 1:17-cv-10169) by four of the same plaintiffs who commenced the California State Court Actions, and two additional plaintiffs, alleging claims under Sections 11 and 12(a)(2) of the Securities Act against the Company, certain of the Company’s current and former directors and officers, and the underwriters of the Company’s IPO, and alleging claims under Section 15 of the Securities Act against certain of the Company’s current and former directors and officers. This action is referred to as the “Massachusetts Federal Court Action.” The plaintiffs in the Massachusetts Federal Court Action filed a consolidated amended complaint on August 9, 2017. The Company subsequently moved to dismiss. On January 19, 2018, the court held oral argument on the motion to dismiss. On February 23, 2018, the court entered an order denying the motion to dismiss for certain defendants only with respect to their motion seeking dismissal for failure to timely serve the complaint and indicated that it will address the substantive grounds for dismissal raised by all defendants at a later date. The complaints in all of the actions listed above allege that the Company’s registration statement used in connection with its IPO failed to disclose that the Company was unprepared or unable to comply with certain regulatory special controls and to provide the FDA with a postmarket surveillance study on the Company’s ReWalk Personal device, and that, as a result of such alleged omission, the plaintiffs suffered damages. The Massachusetts Federal Court Action also alleges that certain statements issued by the Company after its IPO are materially misleading because they omitted certain information. The Company believes that the allegations made in the complaints are without merit and intends to defend itself vigorously against the complaints relating to the three pending actions. Based on information currently available and the early stage of the litigation, the Company is unable to reasonably estimate a possible loss or range of possible losses, if any, with regard to these lawsuits; therefore, no litigation reserve has been recorded in the Company's consolidated balance sheets as of March 31, 2018. The Company will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times when it is probable that a loss will be incurred and the amount of the loss is reasonably estimable.

Research Collaboration Agreemen

Research Collaboration Agreement and License Agreement	3 Months Ended
	Mar. 31, 2018
Research and Development [Abstract]
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	NOTE 6:- RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Research Collaboration Agreement (“Collaboration Agreement”) and an Exclusive License Agreement (“License Agreement”) with Harvard. Under the Collaboration Agreement, Harvard and the Company have agreed to collaborate on research regarding the development of lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Company has committed to pay in quarterly installments for the funding of this research, subject to a minimum funding commitment under applicable circumstances. The Collaboration Agreement will expire on May 16, 2021. Under the Harvard License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The Harvard License Agreement requires the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of March 31, 2018, in light of the achievement of a milestone, the Company recorded a liability which is included in the total expenses recorded during the three months ended March 31, 2018. The Company continues to evaluate the likelihood that other milestones will be achieved on a quarterly basis. Moreover, s ince such royalties are dependent on future product sales which are neither determinable nor reasonably estimable, these royalty payments are not recorded on condensed consolidated balance sheet as of March 31, 2018. The Company's total payment obligation under the Collaboration Agreement and the Harvard License Agreement is $6.5 million, some of which is subject to a minimum funding commitment under applicable circumstances as indicated above. The Company has recorded expense in the amount of $530 thousand which is part of the total payment obligation indicated above, as research and development expenses related to the Harvard License Agreement and to the Collaboration Agreement for the three months ended March 31, 2018. No withholding tax was deducted from the Company's payments to Harvard in respect of the Collaboration Agreement and License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
SHAREHOLDERS' EQUITY	NOTE 7:- SHAREHOLDERS’ EQUITY a. Share option plans: As of March 31, 2018, and December 31, 2017, the Company had reserved 2,451,983 a Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year. Any option that is forfeited or canceled before expiration becomes available for future grants under the 2014 Plan. The Company did not grant options during the three month period ended March 31, 2017. The fair value for options granted during the three months ended March 31, 2018 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions: Three Months Ended March 31, 2018 Expected volatility 61% Risk-free rate 2.74% Dividend yield —% Expected term (in years) 6.11 Share price $1.15 The fair value of restricted share units (“RSUs”) granted is determined based on the price of the Company's ordinary shares on the date of grant. A summary of employee options to purchase ordinary shares and RSUs during the three months ended March 31, 2018 is as follows: Three Months Ended March 31, 2018 Number Average exercise price Average remaining contractual life (in years) (1) Aggregate intrinsic value (in thousands) Options and RSUs outstanding at the beginning of the period 1,846,797 $ 1.86 6.33 $ 586 Options granted 96,525 1.15 RSUs granted 17,857 — Options exercised (2) — — RSUs vested (2) (97,575 ) — RSUs forfeited (27,879 ) — Options forfeited (36,820 ) 10.38 Options and RSUs outstanding at the end of the period 1,798,905 $ 1.76 6.28 $ 517 Options exercisable at the end of the period 1,021,753 $ 2.43 5.34 $ 9 (1) Calculation of weighted average remaining contractual term does not include RSUs, which have an indefinite contractual term. (2) During the three months ended March 31, 2018, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 96,962 ordinary shares. The weighted average grant date fair value of options granted during the three months ended March 31, 2018 was $0.675. The Company did not grant options during the three month period ended March 31, 2017. The weighted average grant date fair value of RSUs granted during the three months ended March 31, 2018 was $1.15. The Company did not grant RSUs to any of its employees during the three month periods ended March 31, 2017. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. No options were exercised during the three months ended March 31, 2018, and the total intrinsic value of options exercised for the three months ended March 31, 2017 was $25 thousand. As of March 31, 2018, there were $3.4 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company's 2012 Equity Incentive Plan and its 2014 Plan. This cost is expected to be recognized over a period of approximately 1.8 years. The number of options and RSUs outstanding as of March 31, 2018 is set forth below, with options separated by range of exercise price. Range of exercise price Options and RSUs outstanding as of March 31, 2018 Weighted average remaining contractual life (years) (1) Options exercisable as of March 31, 2018 Weighted average remaining contractual life (years) (1) RSUs only 461,474 — — — $0.82 31,806 2.79 31,806 2.79 $1.32 426,617 5.45 330,092 4.15 $1.48 755,761 6.71 554,608 5.81 $6.80- $8.99 90,443 7.54 74,209 7.54 $9.22- $10.98 15,358 7.39 14,608 7.37 $19.62-$20.97 17,446 6.69 16,430 6.68 1,798,905 6.28 1,021,753 5.34 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. b. Share-based awards to non-employee consultants: The Company granted 20,454 fully vested RSUs during the three months ended March 31, 2018 to a non-employee consultant. As of March 31, 2018, there are no outstanding options or RSUs held by non-employee consultants. c. Warrants to purchase ordinary shares: The following table summarizes information about warrants outstanding and exercisable as of March 31, 2018: Issuance date Warrants outstanding Exercise price per warrant Warrants exercisable Contractual term (number) (number) July 14, 2014 (1) 403,804 $ 10.08 403,804 July 13, 2018 December 30, 2015 (2) 119,295 $ 9.64 119,295 See footnote (2) November 1, 2016 (3) 2,437,500 $ 4.75 2,437,500 November 1, 2021 December 28, 2016 (4) 47,717 $ 9.64 47,717 See footnote (4) 3,008,316 3,008,316 (1) Represents warrants to purchase ordinary shares at an exercise price of $10.08 per share, which were granted on July 14, 2014 as part of our series E investment round. (2) Represents shares issuable upon the exercise of warrants to purchase ordinary shares at an exercise price of $9.64 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of March 31, 2018. (3) Represents warrants issued as part of our follow-on offering in November 2016. The exercise price and the number of ordinary shares into which the warrants may be exercised are subject to adjustment upon certain corporate events, including stock splits, reverse stock splits, combinations, stock dividends, recapitalizations, reorganizations and certain other events. Our board of directors may also determine to make such adjustments to the exercise price and number of ordinary shares to be issued upon exercise based on similar events, including the granting of stock appreciation rights, phantom stock rights or other rights with equity features. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate. (4) Represents warrants to purchase 47,717 ordinary shares that were issued as part of the $8.0 million drawdown under the Loan Agreement that occurred on December 28, 2016. See footnote 2 for exercisability terms. d. Share-based compensation expense for employees and non-employees: The Company recognized non-cash share-based compensation expense for both employees and non-employees in the consolidated statements of operations as follows (in thousands): Three Months Ended March 31, 2018 2017 Cost of revenues $ 4 $ 28 Research and development, net 114 113 Sales and marketing, net 155 185 General and administrative 523 525 Total $ 796 $ 851 e. At-the-market offering program: On May 10, 2016, the Company entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Jaffray, pursuant to which it may offer and sell, from time to time, ordinary shares having an aggregate offering price of up to $25 million, through Piper Jaffray acting as its agent. As of March 31, 2018 the Company could raise up to a remaining $10.2 million under its ATM Offering Program, subject to a limitation on sales under the Company’s effective Form S-3 limiting sales under such Form S-3 to $13.7 million during any 12-month period. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Jaffray will use its commercially reasonable efforts to sell on the Company’s behalf all of the ordinary shares requested to be sold by the Company, consistent with its normal trading and sales practices. Piper Jaffray may also act as principal in the sale of ordinary shares under the Equity Distribution Agreement. Sales may be made under the Company's registration statement on Form S-3, which was declared effective on May 9, 2016 (the “Form S-3”), in what may be deemed “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “ATM Offering Program”). Sales may be made directly on or through the NASDAQ Capital Market, the existing trading market for the Company's ordinary shares, to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions. Piper Jaffray is entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold through it as agent under the Equity Distribution Agreement. Where Piper Jaffray acts as principal in the sale of ordinary shares under the Equity Distribution Agreement, such rate of compensation will not apply, but in no event will the total compensation of Piper Jaffray, when combined with the reimbursement of Piper Jaffray for the out-of-pocket fees and disbursements of its legal counsel, exceed 8.0% of the gross proceeds received from the sale of the ordinary shares. The Company is not required to sell any of its ordinary shares at any time. During the three months ended March 31, 2018, the Company issued and sold 389,400 ordinary shares at an average price of $1.13 per share under its ATM Offering Program. The gross proceeds to the Company were $440 thousand, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $50 thousand were $390 thousand. As a result, from the inception of the ATM Offering Program in May 2016 until March 31, 2018, the Company had sold 6,694,546 ordinary shares under the ATM Offering Program for gross proceeds of $14.8 million and net proceeds to the Company of $13.8 million (after commissions, fees and expenses). Additionally, as of that date, the Company had paid Piper Jaffray compensation of $444 thousand and had incurred total expenses of approximately $948 thousand in connection with the ATM Offering Program.

Financial Expenses, Net

Financial Expenses, Net	3 Months Ended
	Mar. 31, 2018
Other Income and Expenses [Abstract]
FINANCIAL EXPENSES, NET	NOTE 8:- FINANCIAL EXPENSES, NET The components of financial expenses, net were as follows (in thousands): Three Months Ended March 31, 2018 2017 Foreign currency transactions and other $ (19 ) $ (19 ) Financial expenses related to loan agreement with Kreos 495 739 Bank commissions 9 11 $ 485 $ 731

Geographic Information and Majo

Geographic Information and Major Customer and Product Data	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	NOTE 9:- GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling systems and services (see Note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas: Three Months Ended March 31, 2018 2017 Revenues based on customer’s location : Israel $ — $ — United States 1,178 2,099 Europe 341 400 Asia-Pacific 2 — Latin America 58 — Total revenues $ 1,579 $ 2,499 March 31, December 31, 2018 2017 Long-lived assets by geographic region (*): Israel $ 268 $ 298 United States 300 342 Germany 188 200 $ 756 $ 840 (*) Long-lived assets are comprised of property and equipment, net. March 31, December 31, 2018 2017 Major customer data as a percentage of total revenues: Customer A 37.0 % 35.2 %

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10:- SUBSEQUENT EVENTS On May 15, 2018, following the receipt of shareholder approval under the rules of The Nasdaq Stock Market LLC (“Nasdaq”) and Israeli law, we closed the first tranche of the investment agreement, dated March 6, 2018, with Timwell, issuing 4,000,000 ordinary shares to Timwell for gross proceeds of $5 million and net proceeds of $4.4 million after deducting offering expenses in the amount of $600 thousand. The table below shows, on a pro forma Pro Forma Balance Sheet Actual Adjustments Pro Forma ASSETS CURRENT ASSETS Cash and cash equivalents $ 8,818 $ 4,400 $ 13,218 Trade receivable, net 1,566 — 1,566 Prepaid expenses and other current assets 2,018 — 2,018 Inventories 3,480 — 3,480 Total current assets 15,882 4,400 20,282 LONG-TERM ASSETS Other long term assets 1,082 — 1,082 Property and equipment, net 756 — 756 Total long-term assets 1,838 — 1,838 Total assets $ 17,720 $ 4,400 $ 22,120 LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIENCY) CURRENT LIABILITIES Current maturities of long term loan $ 6,441 — $ 6,441 Trade payables 2,873 — 2,873 Employees and payroll accruals 926 — 926 Deferred revenues and customers advances 129 — 129 Other current liabilities 428 — 428 Total current liabilities 10,797 — 10,797 LONG-TERM LIABILITIES Long term loan, net of current maturities 7,796 — 7,796 Deferred revenues 330 — 330 Other long-term liabilities 296 — 296 Total long-term liabilities 8,422 — 8,422 Total liabilities 19,219 — 19,219 COMMITMENTS AND CONTINGENT LIABILITIES Shareholders’ equity (deficiency): Share capital Ordinary shares NIS 0.01 par value- Authorized: 250,000,000 shares at March 31, 2018; Issued and outstanding: 30,510,455 shares at March 31, 2018. 86 11 97 Receivables on account of shares (42 ) — (42 ) Additional paid-in capital 136,027 4,389 140,416 Accumulated deficit (137,570 ) — (137,570 ) Total shareholders’ equity (deficiency) (1,499 ) 4,400 2,901 Total liabilities and shareholders’ equity (deficiency) $ 17,720 $ 4,400 $ 22,120

Significant Accounting Polici19

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Revenue Recognition	b. Revenue Recognition The Company generate revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. On January 1, 2018, we adopted Topic 606 using the modified retrospective method for contracts that were not completed as of January 1, 2018. Under the modified retrospective method, we recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. This adjustment did not have a material impact on our condensed consolidated financial statements. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under Revenue Recognition ("Topic 605"). The adoption of Topic 606 represents a change in accounting principle that will provide financial statement readers with enhanced revenue recognition disclosures. In accordance with Topic 606, revenue is recognized when obligations under the terms of a contract with our customer are satisfied; generally this occurs with the transfer of control of our products or services. Revenue is measured as the amount of consideration to which we expect to be entitled in exchange for transferring products or providing services. To achieve this core principle, the Company applies the following five steps: 1. Identify the contract with a customer A contract with a customer exists when (i) the Company enters into a written agreement with a customer that defines each party's rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) both parties to the contract are committed to perform their respective obligations, (iii) the contract has commercial substance, and (iv) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer's intent and ability to pay the promised consideration. The Company applies judgment in determining the customer's ability and intention to pay, which is based on a variety of factors including the customer's payment history or, in the case of a new customer, published credit and financial information pertaining to the customer. 2. Identify the performance obligations in the contract Performance obligations promised in a contract are identified based on the products or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the product or service either on its own or together with other resources that are readily available from the Company, and are distinct in the context of the contract, whereby the transfer of the products or services is separately identifiable from other promises in the contract. 3. Determine the transaction price The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer. To the extent the transaction price is variable, revenue is recognized at an amount equal the consideration to which the Company expects to be entitled. This estimate includes customer sales incentives which are accounted for as a reduction to revenue and estimated using either the expected value method or the most likely amount method, depending on the nature of the program. As a result of the Company's adoption of this standard, the majority of the amounts that were historically classified as bad debt expense, primarily related to self-payers customers, are now considered an implicit price concession in determining net revenue. Accordingly, the Company recognized uncollectible balances associated with self-payers customers as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within general and administrative expenses. Shipping and handling costs charged to customers are included in net sales. Determining the transaction price requires significant judgment, which is discussed by revenue category in further detail below. In practice, we do not offer extended payment terms beyond one year to customers. As such, we do not adjust our consideration for financing arrangements. 4. Allocate the transaction price to performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis unless a portion of the variable consideration related to the contract is allocated entirely to a performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. 5. Recognize revenue when or as the Company satisfies a performance obligation The Company generally satisfies performance obligations at a point in time, once the customer has obtained the legal title to the items purchased or service provided. For systems sold to rehabilitation facilities, the Company includes training and considers the elements in the arrangement to be a single performance obligation. In accordance with ASC 606, the Company has concluded that the training is essential to the functionality of the Company’s systems. Therefore the Company recognizes revenue for the system and training only after delivery in accordance with the agreement delivery terms to the customer and after the training has been completed. For sales of Personal systems to end users, and for sales of Personal or Rehabilitation systems to third party distributors, the Company does not provide training to the end user as this training is completed by the Rehabilitation centers or by the distributor that have previously completed the ReWalk Training program. Therefore the Company recognizes revenue in such sales upon delivery. Revenue is recognized based on the transaction price at the time the related performance obligation is satisfied by transferring a promised product or service to a customer. The Company generally does not grant a right of return for its products. There have been a few occasions in which the Company experienced a return of its products. Therefore, the Company records reductions to revenue for expected future product returns based on the Company’s historical experience. Disaggregation of Revenues March 31, March 31, 2018 2017 Units placed $ 1,528 $ 2,443 Spare parts and warranties 51 56 Total Revenues $ 1,579 $ 2,499 Units placed We currently offer two products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is currently designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is currently designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides individuals access to valuable exercise and therapy. It also enables individuals to evaluate their capacity for using ReWalk Personal in the future. Units placed includes revenue from sales of a ReWalk Personal or ReWalk Rehabilitation. We also offer a Rent-to-Purchase model in which we recognize revenue according to the agreed rental monthly fee. For units placed, we transfer control and recognize a sale or a rental revenue when title has passed to our customer. Each unit placed is considered an independent, unbundled performance obligation. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. For spare part sales, we transfer control and recognize a sale when title has passed to our customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, we updated our service policy to include a five- year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. Contract balances March 31, December 31, 2018 2017 Trade receivable, net $ 1,566 $ 1,103 Deferred revenues (1) $ 459 $ 385 (1) $72 thousand of December 31, 2017 deferred revenues balance were recognized as revenues during the three months ended March 31, 2018. The Company has applied the practical expedient allowed within the guidance to expense sales commissions when incurred as the amortization period would be for one year or less. Typical timing of payment The timing of satisfaction of our performance obligations does not significantly vary from the typical timing of payment. Typical payment terms are based on payment terms as established in our contracts. For some contracts we may be entitled to receive an advance payment. Transaction price allocated to remaining performance obligations For the three months ended March 31, 2018, revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material. The Company’s unfilled performance obligations as of March 31, 2018 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $459 thousand, which is fulfilled over 1-5 years.
Recent Accounting Pronouncements	c. Recent Accounting Pronouncements: Share Based Compensation Cash Flows On November 17, 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force) Recent Accounting Pronouncements Not Yet Adopted Leases whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a manner similar to the accounting under existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840, "Leases". The guidance is effective for the interim and annual periods beginning on or after December 15, 2018. The Company is currently evaluating the impact that ASU 2016-02 will have on its consolidated financial statements and related disclosures. Income Taxes Income Tax Accounting Implications of the Tax Cuts and Jobs Act
Concentrations of Credit Risks	d. Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. March 31, December 31, 2018 2017 Customer A 33 % *) Customer B *) 17 % Customer C *) 14 % Customer D *) 10 % *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of March 31, 2018 and December 31, 2017 trade receivables are presented net of allowance for doubtful accounts in the amount of $125 thousand and net of sales return reserve of $105 thousand as of March 31, 2018 and December 31, 2017.
Warranty provision	e. Warranty provision The Company provided a two-year standard warranty for its products, In the beginning of 2018 we updated our service policy for new devices sold to include five-year warranties. The Company determined that the first two years of warranty is an assurance-type warranty and records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in thousands Balance at December 31, 2017 $ 488 Provision 58 Usage (70 ) Balance at March 31, 2018 $ 476

Significant Accounting Polici20

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of revenue recognition based on the transaction price and related performance obligation	March 31, March 31, 2018 2017 Units placed $ 1,528 $ 2,443 Spare parts and warranties 51 56 Total Revenues $ 1,579 $ 2,499
Schedule of trade receivables and deferred revunues	March 31, December 31, 2018 2017 Trade receivable, net $ 1,566 $ 1,103 Deferred revenues (1) $ 459 $ 385 (1) $72 thousand of December 31, 2017 deferred revenues balance were recognized as revenues during the three months ended March 31, 2018.
Schedule of concentration of credit risk	March 31, December 31, 2018 2017 Customer A 33 % *) Customer B *) 17 % Customer C *) 14 % Customer D *) 10 % *) Less than 10%
Schedule of product warranty liability	US Dollars in thousands Balance at December 31, 2017 $ 488 Provision 58 Usage (70 ) Balance at March 31, 2018 $ 476

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Components of inventory	March 31, December 31, 2018 2017 Finished products $ 3,480 $ 3,643 $ 3,480 $ 3,643

Commitments and Contingent Li22

Commitments and Contingent Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease commitments	2018 $ 441 2019 586 2020 594 2021 593 2022 601 And Thereafter 1,106 Total $ 3,921

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Black-Scholes-Merton option pricing model assumptions	Three Months Ended March 31, 2018 Expected volatility 61 % Risk-free rate 2.74 % Dividend yield — % Expected term (in years) 6.11 Share price $ 1.15
Summary of employee options to purchase ordinary shares and RSUs	Three Months Ended March 31, 2018 Number Average exercise price Average remaining contractual life (in years) (1) Aggregate intrinsic value (in thousands) Options and RSUs outstanding at the beginning of the period 1,846,797 $ 1.86 6.33 $ 586 Options granted 96,525 1.15 RSUs granted 17,857 — Options exercised (2) — — RSUs vested (2) (97,575 ) — RSUs forfeited (27,879 ) — Options forfeited (36,820 ) 10.38 Options and RSUs outstanding at the end of the period 1,798,905 $ 1.76 6.28 $ 517 Options exercisable at the end of the period 1,021,753 $ 2.43 5.34 $ 9 (1) Calculation of weighted average remaining contractual term does not include RSUs, which have an indefinite contractual term. (2) During the three months ended March 31, 2018, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 96,962 ordinary shares.
Schedule of options and RSUs outstanding	Range of exercise price Options and RSUs outstanding as of March 31, 2018 Weighted average remaining contractual life (years) (1) Options exercisable as of March 31, 2018 Weighted average remaining contractual life (years) (1) RSUs only 461,474 — — — $0.82 31,806 2.79 31,806 2.79 $1.32 426,617 5.45 330,092 4.15 $1.48 755,761 6.71 554,608 5.81 $6.80- $8.99 90,443 7.54 74,209 7.54 $9.22- $10.98 15,358 7.39 14,608 7.37 $19.62-$20.97 17,446 6.69 16,430 6.68 1,798,905 6.28 1,021,753 5.34 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of warrants outstanding and exercisable	Issuance date Warrants outstanding Exercise price per warrant Warrants exercisable Contractual term (number) (number) July 14, 2014 (1) 403,804 $ 10.08 403,804 July 13, 2018 December 30, 2015 (2) 119,295 $ 9.64 119,295 See footnote (2) November 1, 2016 (3) 2,437,500 $ 4.75 2,437,500 November 1, 2021 December 28, 2016 (4) 47,717 $ 9.64 47,717 See footnote (4) 3,008,316 3,008,316 (1) Represents warrants to purchase ordinary shares at an exercise price of $10.08 per share, which were granted on July 14, 2014 as part of our series E investment round. (2) Represents shares issuable upon the exercise of warrants to purchase ordinary shares at an exercise price of $9.64 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of March 31, 2018. (3) Represents warrants issued as part of our follow-on offering in November 2016. The exercise price and the number of ordinary shares into which the warrants may be exercised are subject to adjustment upon certain corporate events, including stock splits, reverse stock splits, combinations, stock dividends, recapitalizations, reorganizations and certain other events. Our board of directors may also determine to make such adjustments to the exercise price and number of ordinary shares to be issued upon exercise based on similar events, including the granting of stock appreciation rights, phantom stock rights or other rights with equity features. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate. (4) Represents warrants to purchase 47,717 ordinary shares that were issued as part of the $8.0 million drawdown under the Loan Agreement that occurred on December 28, 2016. See footnote 2 for exercisability terms.
Schedule of non-cash share-based compensation expense	Three Months Ended March 31, 2018 2017 Cost of revenues $ 4 $ 28 Research and development, net 114 113 Sales and marketing, net 155 185 General and administrative 523 525 Total $ 796 $ 851

Financial Expenses, Net (Tables

Financial Expenses, Net (Tables)	3 Months Ended
	Mar. 31, 2018
Other Income and Expenses [Abstract]
Schedule of financial expenses, net	Three Months Ended March 31, 2018 2017 Foreign currency transactions and other $ (19 ) $ (19 ) Financial expenses related to loan agreement with Kreos 495 739 Bank commissions 9 11 $ 485 $ 731

Geographic Information and Ma25

Geographic Information and Major Customer and Product Data (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Schedule of revenues within geographic areas	Three Months Ended March 31, 2018 2017 Revenues based on customer’s location : Israel $ — $ — United States 1,178 2,099 Europe 341 400 Asia-Pacific 2 — Latin America 58 — Total revenues $ 1,579 $ 2,499
Schedule of long-lived assets by geographic region	March 31, December 31, 2018 2017 Long-lived assets by geographic region (*): Israel $ 268 $ 298 United States 300 342 Germany 188 200 $ 756 $ 840 (*) Long-lived assets are comprised of property and equipment, net.
Schedule of major customer data as a percentage of total revenues	March 31, December 31, 2018 2017 Major customer data as a percentage of total revenues: Customer A 37.0 % 35.2 %

Subsequent Events (Tables)

Subsequent Events (Tables)	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Summary of pro farma adjustments of financial statements	Pro Forma Balance Sheet Actual Adjustments Pro Forma ASSETS CURRENT ASSETS Cash and cash equivalents $ 8,818 $ 4,400 $ 13,218 Trade receivable, net 1,566 — 1,566 Prepaid expenses and other current assets 2,018 — 2,018 Inventories 3,480 — 3,480 Total current assets 15,882 4,400 20,282 LONG-TERM ASSETS Other long term assets 1,082 — 1,082 Property and equipment, net 756 — 756 Total long-term assets 1,838 — 1,838 Total assets $ 17,720 $ 4,400 $ 22,120 LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIENCY) CURRENT LIABILITIES Current maturities of long term loan $ 6,441 — $ 6,441 Trade payables 2,873 — 2,873 Employees and payroll accruals 926 — 926 Deferred revenues and customers advances 129 — 129 Other current liabilities 428 — 428 Total current liabilities 10,797 — 10,797 LONG-TERM LIABILITIES Long term loan, net of current maturities 7,796 — 7,796 Deferred revenues 330 — 330 Other long-term liabilities 296 — 296 Total long-term liabilities 8,422 — 8,422 Total liabilities 19,219 — 19,219 COMMITMENTS AND CONTINGENT LIABILITIES Shareholders’ equity (deficiency): Share capital Ordinary shares NIS 0.01 par value- Authorized: 250,000,000 shares at March 31, 2018; Issued and outstanding: 30,510,455 shares at March 31, 2018. 86 11 97 Receivables on account of shares (42 ) — (42 ) Additional paid-in capital 136,027 4,389 140,416 Accumulated deficit (137,570 ) — (137,570 ) Total shareholders’ equity (deficiency) (1,499 ) 4,400 2,901 Total liabilities and shareholders’ equity (deficiency) $ 17,720 $ 4,400 $ 22,120

General (Details)

General (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	23 Months Ended
	Mar. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	May 10, 2016
General (Textual)
Number of shares sold	6,694,546	6,694,546
Average price	$ 2.21	$ 2.21
Maximum amount which can be raised under ATM offering program				$ 25,000
Accumulated deficit	$ (137,570)	$ (137,570)	$ (131,220)
Limitation on sales, description	The Company could raise up to a remaining $10.2 million under its ATM Offering Program, subject to a limitation on sales under the Company’s effective Form S-3 limiting sales under such Form S-3 to $13.7 million during any 12-month period.
ATM Offering Program [Member]
General (Textual)
Number of shares sold	389,400	389,400
Average price	$ 1.13	$ 1.13
Gross proceed amount	$ 440	$ 14,800
Net aggregate proceeds		13,800
Aggregate amount of fees and offering expenses		$ 948
Aggregate amount of fees	50
Aggregate amount of offering expenses	$ 390

Significant Accounting Polici28

Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Total Revenues	$ 1,579	$ 2,499
Units Placed [Member]
Total Revenues	1,528	2,443
Spare parts and warranties [Member]
Total Revenues	$ 51	$ 56

Significant Accounting Polici29

Significant Accounting Policies (Details 1) - USD ($) $ in Thousands		Mar. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Trade receivable, net		$ 1,566	$ 1,103
Deferred revenues	[1]	$ 459	$ 385
[1]	$72 thousand of December 31, 2017 deferred revenues balance were recognized as revenues during the three months ended March 31, 2018.

Significant Accounting Polici30

Significant Accounting Policies (Details 2)	3 Months Ended		12 Months Ended
	Mar. 31, 2018		Dec. 31, 2017
Customer A [Member]
Concentration risk	33.00%			[1]
Customer B [Member]
Concentration risk		[1]	17.00%
Customer C [Member]
Concentration risk		[1]	14.00%
Customer D [Member]
Concentration risk		[1]	10.00%
[1]	Less than 10%

Significant Accounting Polici31

Significant Accounting Policies (Details 3) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at December 31, 2017	$ 488
Provision	58
Usage	(70)
Balance at March 31, 2018	$ 476

Significant Accounting Polici32

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Significant Accounting Policies (Textual)
Allowance for doubtful accounts	$ 125	$ 125
Net of sales return reserve	105	$ 105
Deferred revenues recognized	$ 72
Estimated revenue expected to be recognized, description	The estimated revenue expected to be recognized in the future related to the service type warranty is $459 thousand, which is fulfilled over 1-5 years.

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished products	$ 3,480	$ 3,643
Inventory	$ 3,480	$ 3,643

Commitments and Contingent Li34

Commitments and Contingent Liabilities (Details) $ in Thousands	Mar. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 441
2,019	586
2,020	594
2,021	593
2,022	601
And Thereafter	1,106
Total	$ 3,921

Commitments and Contingent Li35

Commitments and Contingent Liabilities (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Mar. 31, 2018
Commitments and Contingent Liabilities (Textual)
Non-cancelable outstanding obligations		$ 317
Maximum penalties payable on early release of agreement		57
Total fund received		1,790
Amount pledged as security		$ 850
Lease expiration, term		These leases expire between 2018 and 2025.
Initial public offering [Member]
Commitments and Contingent Liabilities (Textual)
Description of conversion ratio	Ordinary shares in a conversion ratio of 1 to 1.
IIA [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received		$ 1,970
Royalty bearing grants		1,570
Royalties paid		50
Contingent liability		$ 1,500
Percentage of grant received		100.00%
IIA [Member] | Minimum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties		3.00%
IIA [Member] | Maximum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties		3.50%
IIA [Member] | Series A Preferred Stock [Member]
Commitments and Contingent Liabilities (Textual)
Amount received in consideration of preferred shares		$ 400
Convertible preferred shares		5,237
BIRD [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received		$ 500
Percentage of obligation to pay royalties		5.00%
BIRD [Member] | Maximum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties		150.00%
RRL and RRG [Member]
Commitments and Contingent Liabilities (Textual)
Lease expiration, term		Operating lease agreements expiring at various dates in between 2018 and 2020.
Kreos Capital [Member]
Commitments and Contingent Liabilities (Textual)
Line of credit		$ 20,000

Research Collaboration Agreem36

Research Collaboration Agreement and License Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	May 16, 2016	Mar. 31, 2018	Mar. 31, 2017
Research Collaboration Agreement and License Agreement (Textual)
Total payment obligation		$ 6,500
Research and development expenses		2,151	$ 1,430
Collaboration Agreement [Member]
Research Collaboration Agreement and License Agreement (Textual)
Research collaboration agreement expire date	May 16, 2021
Harvard License Agreement and Collaboration Agreement [Member]
Research Collaboration Agreement and License Agreement (Textual)
Research and development expenses		$ 530

Shareholders' Equity (Details)

Shareholders' Equity (Details)	3 Months Ended
	Mar. 31, 2018$ / shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected volatility	61.00%
Risk-free rate	2.74%
Dividend yield
Expected term (in years)	6 years 1 month 9 days
Share price	$ 1.15

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Employee Stock Option and Restricted Stock Units RSUs [Member]
Number
Options and RSU's outstanding at the beginning of the period	1,846,797
RSUs granted	17,857
Options and RSU's outstanding at the end of the period	1,798,905
Average exercise price
Options and RSUs outstanding at the beginning of the period | $ / shares	$ 1.86
Options and RSUs outstanding at the end of the period | $ / shares	$ 1.76
Average remaining contractual life (in years)
Options and RSUs outstanding, beginning	6 years 3 months 29 days	[1]
Options and RSUs outstanding, ending	6 years 3 months 11 days	[1]
Aggregate intrinsic value (in thousands)
Options and RSUs outstanding at beginning of the period | $	$ 586
Options and RSUs outstanding at the end of the period | $	$ 517
Employee Stock Option [Member]
Number
Options granted	96,525
Options exercised		[2]
Options forfeited	(36,820)
Options exercisable at the end of the period	1,021,753
Average exercise price
Options granted | $ / shares	$ 1.15
Options exercised | $ / shares		[2]
Options forfeited | $ / shares	10.38
Options exercisable at the end of the period | $ / shares	$ 2.43
Average remaining contractual life (in years)
Options exercisable at the end of the period	5 years 4 months 2 days	[1]
Aggregate intrinsic value (in thousands)
Options exercisable at the end of the period | $	$ 9
Restricted Stock Units (RSUs) [Member]
Number
Options granted	20,454
RSUs vested	(97,575)	[2]
RSUs forfeited	(27,879)
[1]	Calculation of weighted average remaining contractual term does not include RSUs, which have an indefinite contractual term.
[2]	During the three months ended March 31, 2018, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 96,962 ordinary shares.

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - $ / shares	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Employee Stock Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options exercisable	1,021,753
Options exercisable weighted average remaining contractual life (years)	5 years 4 months 2 days
Employee Stock Option [Member] | Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding	31,806
Options outstanding weighted average remaining contractual life (years)	2 years 9 months 15 days
Options exercisable	31,806
Options exercisable weighted average remaining contractual life (years)	2 years 9 months 15 days
Exercise price	$ 0.82
Employee Stock Option [Member] | Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding	426,617
Options outstanding weighted average remaining contractual life (years)	5 years 5 months 12 days
Options exercisable	330,092
Options exercisable weighted average remaining contractual life (years)	4 years 1 month 24 days
Exercise price	$ 1.32
Employee Stock Option [Member] | Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding	755,761
Options outstanding weighted average remaining contractual life (years)	6 years 8 months 16 days
Options exercisable	554,608
Options exercisable weighted average remaining contractual life (years)	5 years 9 months 22 days
Exercise price	$ 1.48
Employee Stock Option [Member] | Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, minimum	6.80
Range of exercise price, maximum	$ 8.99
Options outstanding	90,443
Options outstanding weighted average remaining contractual life (years)	7 years 6 months 15 days
Options exercisable	74,209
Options exercisable weighted average remaining contractual life (years)	7 years 6 months 15 days
Employee Stock Option [Member] | Exercise Price Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, minimum	$ 9.22
Range of exercise price, maximum	$ 10.98
Options outstanding	15,358
Options outstanding weighted average remaining contractual life (years)	7 years 4 months 21 days
Options exercisable	14,608
Options exercisable weighted average remaining contractual life (years)	7 years 4 months 13 days
Employee Stock Option [Member] | Exercise Price Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, minimum	$ 19.62
Range of exercise price, maximum	$ 20.97
Options outstanding	17,446
Options outstanding weighted average remaining contractual life (years)	6 years 8 months 9 days
Options exercisable	16,430
Options exercisable weighted average remaining contractual life (years)	6 years 8 months 5 days
Employee Stock Option And Restricted Stock Units Rsu [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding weighted average remaining contractual life (years)	6 years 3 months 11 days
Options and RSU's outstanding	1,798,905	1,846,797
Restricted Stock Units (RSUs) [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
RSUs outstanding	461,474

Shareholders' Equity (Details 3

Shareholders' Equity (Details 3)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants outstanding	3,008,316
Warrants exercisable	3,008,316
July 14, 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	403,804	[1]
Exercise price per warrant | $ / shares	$ 10.08	[1]
Warrants exercisable	403,804	[1]
Warrants term	Jul. 13, 2018
December 30, 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	119,295	[2]
Exercise price per warrant | $ / shares	$ 9.64	[2]
Warrants exercisable	119,295	[2]
November 1, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	2,437,500	[3]
Exercise price per warrant | $ / shares	$ 4.75	[3]
Warrants exercisable	2,437,500	[3]
Warrants term	Nov. 1, 2021
December 28, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	47,717	[4]
Exercise price per warrant | $ / shares	$ 9.64	[4]
Warrants exercisable	47,717	[4]
[1]	Represents warrants to purchase ordinary shares at an exercise price of $10.08 per share, which were granted on July 14, 2014 as part of our series E investment round.
[2]	Represents Shares issuable upon the exercise of warrants to purchase ordinary shares at an exercise price of $9.64 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.. None of these warrants had been exercised as of March 31, 2018.
[3]	Represents warrants issued as part of our follow-on offering in November 2016. The exercise price and the number of ordinary shares into which the warrants may be exercised are subject to adjustment upon certain corporate events, including stock splits, reverse stock splits, combinations, stock dividends, recapitalizations, reorganizations and certain other events. Our board of directors may also determine to make such adjustments to the exercise price and number of ordinary shares to be issued upon exercise based on similar events, including the granting of stock appreciation rights, phantom stock rights or other rights with equity features. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate.
[4]	Represents warrants to purchase 47,717 ordinary shares that were issued as part of the $8.0 million drawdown under the Loan Agreement that occurred on December 28, 2016. See footnote 2 for exercisability terms.

Shareholders' Equity (Details 4

Shareholders' Equity (Details 4) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	$ 796	$ 851
Cost of revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	4	28
Research and development, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	114	113
Sales and marketing, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	155	185
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	$ 523	$ 525

Shareholders' Equity (Details T

Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	May 10, 2016	Dec. 31, 2015	Jul. 14, 2014	Dec. 28, 2016	Mar. 31, 2018		Mar. 31, 2017	Dec. 31, 2017	Mar. 31, 2018
Shareholders' Equity (Textual)
Maximum amount which can be raised under ATM offering program	$ 25,000
Stock issuance costs under equity distribution agreement as a percent of gross proceeds	3.00%
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses					$ 348	[1]		$ 9,309
Issuance expenses					$ 12
Expected term of shares					6 years 1 month 9 days
Sale of stock price per share	$ 0.08
Proceeds percentage of sale of the ordinary shares					8.00%
Limitation on sales, description					The Company could raise up to a remaining $10.2 million under its ATM Offering Program, subject to a limitation on sales under the Company’s effective Form S-3 limiting sales under such Form S-3 to $13.7 million during any 12-month period.
Restricted Stock Units (RSUs) [Member]
Shareholders' Equity (Textual)
Options granted (in shares)					20,454
Weighted average grant date fair value, restricted stock units (in USD per share)					$ 1.15
Weighted average grant date fair value, options (in USD per share)					$ 0.675
Aggregate number of ordinary shares that were issued pursuant to RSUs					96,962
Share option plan [Member]
Shareholders' Equity (Textual)
Options granted (in shares)					96,525
Total intrinsic value of options exercised							$ 25
Award vesting period					1 year
Shares reserved for future issuance (in shares)					2,451,983			1,301,521	2,451,983
Unrecognized cost of shares					$ 3,400				$ 3,400
Expected term of shares					1 year 9 months 18 days
ATM Offering Program [Member]
Shareholders' Equity (Textual)
Issuance of ordinary shares (in shares)					389,400
Price per share of shares sold under ATM offering program (in USD per share)					$ 1.13
Issuance of ordinary shares in an ATM offering of ordinary shares, gross of issuance expenses					$ 440
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses					$ 50				13,800
Issuance expenses									$ 948
Sale of ordinary shares					389,400				6,694,546
Compensation payment									$ 444
Gross proceeds									$ 14,800
Series E investment [Member]
Shareholders' Equity (Textual)
Exercise price per share			$ 10.08
Warrants grant date			Jul. 14, 2014
Kreos Capital [Member]
Shareholders' Equity (Textual)
Issuance of ordinary shares (in shares)				47,717
Exercise price per share		$ 9.64
Warrants exercisable, description		Currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.
Drawdown amount under loan agreement				$ 8,000
[1]	See Note 7e to the condensed consolidated financial statements.

Financial Expenses, Net (Detail

Financial Expenses, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Other Income and Expenses [Abstract]
Foreign currency transactions and other	$ (19)	$ (19)
Financial expenses related to loan agreement with Kreos	495	739
Bank commissions	9	11
Financial expenses, net	$ 485	$ 731

Geographic Information and Ma44

Geographic Information and Major Customer and Product Data (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue, Major Customer [Line Items]
Total revenues	$ 1,579	$ 2,499
Israel [Member]
Revenue, Major Customer [Line Items]
Total revenues
United States [Member]
Revenue, Major Customer [Line Items]
Total revenues	1,178	2,099
Europe [Member]
Revenue, Major Customer [Line Items]
Total revenues	341	400
Asia-Pacific [Member]
Revenue, Major Customer [Line Items]
Total revenues	2
Latin America [Member]
Revenue, Major Customer [Line Items]
Total revenues	$ 58

Geographic Information and Ma45

Geographic Information and Major Customer and Product Data (Details 1) - USD ($) $ in Thousands		Mar. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets		$ 756	$ 840
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	268	298
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	300	342
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	$ 188	$ 200
[1]	Long-lived assets are comprised of property and equipment, net.

Geographic Information and Ma46

Geographic Information and Major Customer and Product Data (Details 2)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Total revenues [Member] | Customer A [Member]
Revenue, Major Customer [Line Items]
Concentration risk	37.00%	35.20%

Geographic Information and Ma47

Geographic Information and Major Customer and Product Data (Details Textual)	3 Months Ended
	Mar. 31, 2018segment
Geographic Information and Major Customer and Product Data (Textual)
Number of reportable segments	1

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 8,818	$ 14,567
Trade receivable, net	1,566	1,103
Prepaid expenses and other current assets	2,018	1,625
Inventories	3,480	3,643
Total current assets	15,882	20,938
LONG-TERM ASSETS
Other long term assets	1,082	1,085
Property and equipment, net	756	840
Total long-term assets	1,838	1,925
Total assets	17,720	22,863
CURRENT LIABILITIES
Current maturities of long term loan	6,441	6,441
Trade payables	2,873	1,811
Employees and payroll accruals	926	872
Deferred revenues and customers advances	129	123
Other current liabilities	428	480
Total current liabilities	10,797	9,727
LONG-TERM LIABILITIES
Long term loan, net of current maturities	7,796	8,911
Deferred revenues	330	262
Other long-term liabilities	296	256
Total long-term liabilities	8,422	9,429
Total liabilities	19,219	19,156
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders' equity (deficiency):
Share capital, Ordinary shares NIS 0.01 par value- Authorized: 250,000,000 shares at March 31, 2018 and December 31, 2017; Issued and outstanding: 30,510,455 and 30,003,639 shares at March 31, 2018 and December 31, 2017, respectively	86	84
Receivables on account of shares	(42)
Additional paid-in capital	136,027	134,843
Accumulated deficit	(137,570)	(131,220)
Total shareholders' equity (deficiency)	(1,499)	3,707	$ 8,260
Total liabilities and shareholders' equity (deficiency)	17,720	$ 22,863
Adjustments [Member]
CURRENT ASSETS
Cash and cash equivalents	4,400
Trade receivable, net
Prepaid expenses and other current assets
Inventories
Total current assets	4,400
LONG-TERM ASSETS
Other long term assets
Property and equipment, net
Total long-term assets
Total assets	4,400
CURRENT LIABILITIES
Current maturities of long term loan
Trade payables
Employees and payroll accruals
Deferred revenues and customers advances
Other current liabilities
Total current liabilities
LONG-TERM LIABILITIES
Long term loan, net of current maturities
Deferred revenues
Other long-term liabilities
Total long-term liabilities
Total liabilities
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders' equity (deficiency):
Share capital, Ordinary shares NIS 0.01 par value- Authorized: 250,000,000 shares at March 31, 2018 and December 31, 2017; Issued and outstanding: 30,510,455 and 30,003,639 shares at March 31, 2018 and December 31, 2017, respectively	11
Receivables on account of shares
Additional paid-in capital	4,389
Accumulated deficit
Total shareholders' equity (deficiency)	4,400
Total liabilities and shareholders' equity (deficiency)	4,400
Pro Forma [Member]
CURRENT ASSETS
Cash and cash equivalents	13,218
Trade receivable, net	1,566
Prepaid expenses and other current assets	2,018
Inventories	3,480
Total current assets	20,282
LONG-TERM ASSETS
Other long term assets	1,082
Property and equipment, net	756
Total long-term assets	1,838
Total assets	22,120
CURRENT LIABILITIES
Current maturities of long term loan	6,441
Trade payables	2,873
Employees and payroll accruals	926
Deferred revenues and customers advances	129
Other current liabilities	428
Total current liabilities	10,797
LONG-TERM LIABILITIES
Long term loan, net of current maturities	7,796
Deferred revenues	330
Other long-term liabilities	296
Total long-term liabilities	8,422
Total liabilities	19,219
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders' equity (deficiency):
Share capital, Ordinary shares NIS 0.01 par value- Authorized: 250,000,000 shares at March 31, 2018 and December 31, 2017; Issued and outstanding: 30,510,455 and 30,003,639 shares at March 31, 2018 and December 31, 2017, respectively	97
Receivables on account of shares	(42)
Additional paid-in capital	140,416
Accumulated deficit	(137,570)
Total shareholders' equity (deficiency)	2,901
Total liabilities and shareholders' equity (deficiency)	$ 22,120

Subsequent Events (Details 1)

Subsequent Events (Details 1) - ₪ / shares	Mar. 31, 2018	Dec. 31, 2017
Subsequent Events [Abstract]
Ordinary shares, par value (in ILS per share)	₪ 0.01	₪ 0.01
Ordinary shares, authorized	250,000,000	250,000,000
Ordinary shares, issued	30,510,455	30,003,639
Ordinary shares, outstanding	30,510,455	30,003,639

Subsequent Events (Details Text

Subsequent Events (Details Textual) - Subsequent Event [Member] $ in Thousands	May 15, 2018USD ($)shares
Subsequent Events (Textual)
Issuance of ordinary shares | shares	4,000,000
Gross proceeds	$ 5,000
Net proceeds	4,400
Offering expenses	$ 600